Seminars in Hematology
Volume 46, Issue 2 , Pages 143-157 , April 2009

Treatment of Relapsed/Refractory Multiple Myeloma

  • Efstathios Kastritis

      Affiliations

    • Department of Clinical Therapeutics University of Athens School of Medicine, Athens, Greece
    • ,
  • Antonio Palumbo

      Affiliations

    • Divisione di Ematologia dell'Università di Torino, Azienda Ospedaliera S. Giovanni Battista, Ospedale Molinette, Turin, Italy
    • ,
  • Meletios A. Dimopoulos

      Affiliations

    • Department of Clinical Therapeutics University of Athens School of Medicine, Athens, Greece
    • Corresponding Author InformationAddress correspondence to Meletios A. Dimopoulos, MD, Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, 80 Vas. Sofias Ave, Athens 115 24, Greece

References 

  1. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473
  2. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med. 1986;105:8–11
  3. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498
  4. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer E, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009) [abstract]. J Clin Oncol (Meeting Abstracts). 2006;24(suppl):7521
  5. Dimopoulos MA, Spencer A, Attal M, Prince M, Harousseau J-L, Dmoszynska A, et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010) [abstract]. ASH Annual Meeting Abstracts. 2005;106:6
  6. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–2142
  7. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–2132
  8. Gertz MA, Garton JP, Greipp PR, Witzig TE, Kyle RA. A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia. 1995;9(12):2115–2118
  9. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310:1353–1356
  10. Lokhorst HM, Meuwissen OJ, Bast EJ, Dekker AW. VAD chemotherapy for refractory multiple myeloma. Br J Haematol. 1989;71:25–30
  11. Anderson H, Scarffe JH, Ranson M, Young R, Wieringa GS, Morgenstern GR, et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer. 1995;71:326–330
  12. Phillips JK, Sherlaw-Johnson C, Pearce R, Davies JM, Reilly JT, Newland AC, et al. A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. Leuk Lymphoma. 1995;17:465–472
  13. Gertz MA, Kalish LA, Kyle RA, Hahn RG, Tormey DC, Oken MM. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma (An Eastern Cooperative Oncology Group study). Am J Clin Oncol. 1995;18:475–480
  14. MacLennan IC, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis (The Medical Research Council Working Party for Leukaemia in Adults). Lancet. 1992;339:200–205
  15. Durie BG, Dixon DO, Carter S, Stephens R, Rivkin S, Bonnet J, et al. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol. 1986;4:1227–1237
  16. Giles FJ, Wickham NR, Rapoport BL, Somlo G, Lim SW, Shan J, et al. Cyclophosphamide, etoposide, vincristine, Adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol. Am J Hematol. 2000;63:125–130
  17. Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003;21:2732–2739
  18. Hussein MA, Baz R, Srkalovic G, Agrawal N, Suppiah R, Hsi E, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc. 2006;81:889–895
  19. Zervas K, Dimopoulos MA, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli C, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol. 2004;15:134–138
  20. Hussein MA. Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide. Oncologist. 2003;8(suppl 3):39–45
  21. Baz R, Walker E, Karam M, Choueiri T, Jawde R, Bruening K, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol. 2006;17:1766–1771
  22. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005;105:3058–3065
  23. Biehn SE, Moore DT, Voorhees PM, Garcia RA, Lehman MJ, Dees EC, et al. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 2007;86:211–216
  24. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67:1298–1301
  25. Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S, et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987;70:869–872
  26. Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood. 1993;82:2324–2328
  27. Vesole DH, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R, et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood. 1994;84:950–956
  28. Alexanian R, Dimopoulos M, Smith T, Delasalle K, Barlogie B, Champlin R. Limited value of myeloablative therapy for late multiple myeloma. Blood. 1994;83:512–516
  29. Alexanian R, Dimopoulos MA, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. Blood. 1994;84:4278–4282
  30. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant. 2004;34:161–167
  31. Fassas AB, Barlogie B, Ward S, Jagannath S, Vesole D, Mattox S, et al. Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience. Br J Haematol. 2003;123:484–489
  32. Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, et al. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant. 2002;30:873–878
  33. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? (Results of a multicenter sequential randomized clinical trial). Blood. 1998;92:3131–3136
  34. Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. 2007;109:3588–3594
  35. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102:3447–3454
  36. Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol. 2003;31:73–80
  37. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2002;30:367–373
  38. Einsele H, Schafer HJ, Hebart H, Bader P, Meisner C, Plasswilm L, et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol. 2003;121:411–418
  39. Qazilbash MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer. 2006;106:1084–1089
  40. Kroger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2004;10:698–708
  41. Anderson KC. Lenalidomide and thalidomide: mechanisms of action—similarities and differences. Semin Hematol. 2005;42(suppl 4):S3–S8
  42. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–1571
  43. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492–494
  44. van Rhee F, Dhodapkar M, Shaughnessy JD, Anaissie E, Siegel D, Hoering A, et al. First thalidomide clinical trial in multiple myeloma: a decade. Blood. 2008;112:1035–1038
  45. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2006;132:584–593
  46. Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD, et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res. 2002;8:3377–3382
  47. Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients—report of the Intergroupe Francophone du Myelome (IFM). Hematol J. 2002;3:185–192
  48. Grosbois B, Bellisant E, Moreau P, Attal M, Zerbib R. Thalidomide (Thal) in the treatement of advanced multiple myeloma (MM) (A prospective study of 120 patients [abstract]). Blood. 2001;98:689
  49. Yakoub-Agha I, Doyen C, Hulin C, Marit G, Voillat L, Grosbois B, et al. A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: results of the final analysis of the IFM 01-02 study [abstract]. J Clin Oncol (Meeting Abstracts). 2006;24(suppl):7520
  50. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943–2950
  51. Weber D, Delasalle K, Giralt S, Alexanian R. Thalidomide alone or with dexamethasone for multiple myeloma [abstract]. Blood. 1999;94:604a
  52. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica. 2001;86:399–403
  53. Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol. 2001;12:991–995
  54. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol. 2003;121:768–771
  55. Palumbo A, Bertola A, Falco P, Rosato R, Cavallo F, Giaccone L, et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J. 2004;5:318–324
  56. Palumbo A, Falco P, Ambrosini MT, Petrucci MT, Musto P, Caravita T, et al. Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. Eur J Haematol. 2005;75:391–395
  57. Fermand J-P, Jaccard A, Macro M, Uzunhan Y, Allard C, Castaigne S, et al. A randomized comparison of dexamethasone + thalidomide (Dex/Thal) vs Dex + placebo (Dex/P) in patients (pts) with relapsing multiple myeloma (MM) [abstract]. ASH Annual Meeting Abstracts. 2006;108:3563
  58. Glasmacher A, Hahn C, Hoffmann F, Furkert K, von Lilienfeld-Toal M, Orlopp K, et al. Thalidomide in relapsed or refractory patients with multiple myeloma: monotherapy or combination therapy? (A report from Systematic Reviews [abstract]). ASH Annual Meeting Abstracts. 2005;106:5125
  59. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414–423
  60. Hall VC, El-Azhary RA, Bouwhuis S, Rajkumar SV. Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol. 2003;48:548–552
  61. Barlogie B. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. Semin Hematol. 2003;40(suppl 4):33–38
  62. Moehler TM, Neben K, Benner A, Egerer G, Krasniqi F, Ho AD, et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood. 2001;98:3846–3848
  63. Kropff MH, Lang N, Bisping G, Domine N, Innig G, Hentrich M, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol. 2003;122:607–616
  64. Offidani M, Corvatta L, Marconi M, Visani G, Alesiani F, Brunori M, et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica. 2006;91:133–136
  65. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma. 2003;4:32–35
  66. Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, Polo-Zarzuela M, Sureda A, Barrenetxea C, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia. 2004;18:856–863
  67. Kyriakou C, Thomson K, D'Sa S, Flory A, Hanslip J, Goldstone AH, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol. 2005;129:763–770
  68. Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J. 2004;5:112–117
  69. Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B. Results of a phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT) [abstract 3226]. Blood. 2001;98:775a
  70. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063–3067
  71. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108:3458–3464
  72. Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, et al. A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; preliminary results [abstract]. ASH Annual Meeting Abstracts. 2005;106:1565
  73. Bahlis NJ, Song K, Trieu Y, Roland B, Masih-Khan E, Chang H, et al. Lenalidomide overcomes poor prognosis conferred by del13q and t(4;14) but not del17p13 in multiple myeloma: results of the Canadian MM016 trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110:3597
  74. Reece DE, Masih-Khan E, Chen C, Wang L, Dean S, Kukreti V, et al. Use of Lenalidomide (revlimid +/- corticosteroids in relapsed/refractory multiple myeloma patients with elevated baseline serum creatinine levels. ASH Annual Meeting Abstracts. 2006;108:3548
  75. Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007;47:1466–1475
  76. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. J Clin Oncol (Meeting Abstracts). 2007;25(suppl):LBA8025
  77. Miguel JFS, Dimopoulos M, Weber D, Olesnyckyj M, Yu Z, Zeldis J, et al. Dexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM009/010 sub-analysis) [analysis]. Blood (ASH Annual Meeting Abstracts). 2007;110:2712
  78. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377–2380
  79. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165–172
  80. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–2617
  81. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110:3557–3560
  82. Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer. 2005;104:2141–2148
  83. Hrusovsky I, Emmerich B, Engelhardt M, Kornacker M, Gann C-N, Pliskat H, et al. Bortezomib retreatment in relapsed multiple mycelia - a retrospective multicenter survey [abstract]. ASH Annual Meeting Abstracts. 2007;110:2720
  84. Wolf JL, Richardson P, Schuster M, LeBlanc A, Battleman D, Walters I. Utility of bortezomib retreatment for patients with relapsed multiple myeloma [abstract]. ASH Annual Meeting Abstracts. 2006;108:3532
  85. Conner TM, Doan QD, LeBlanc AL, Walters IB, Beveridge RA. An observational, retrospective analysis of retreatment with bortezomib of mulitple myeloma (MM) patients [abstract]. ASH Annual Meeting Abstracts. 2006;108:3531
  86. Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106:3777–3784
  87. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109:2604–2606
  88. San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008;22:842–849
  89. Roussou M, Kastritis E, Anagnostopoulos A, Psimenou E, Grapsa I, Matsouka C, et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110:2739
  90. Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892–3901
  91. Chanan-Khan A, Miller KC. Velcade, doxil and thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma. Leuk Lymphoma. 2005;46:1103–1104
  92. Ciolli S, Leoni F, Casini C, Breschi C, Santini V, Bosi A. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol. 2008;141:814–819
  93. Ciolli S, Leoni F, Casini C, Breschi C, Bosi A. Liposomal doxorubicin (Myocet) enhances the efficacy of bortezomib, dexamethasone plus thalidomide in refractory myeloma [abstract]. ASH Annual Meeting Abstracts. 2006;108:5087
  94. Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2006;24:937–944
  95. Berenson JR, Yang HH, Vescio RA, Nassir Y, Mapes R, Lee SP, et al. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Ann Hematol. 2008;87:623–631
  96. Popat R, Williams C, Cook M, Craddock C, Basu S, Singer C, et al. Bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma: final results of a phase I/II clinical trial [abstract]. ASH Annual Meeting Abstracts. 2007;110:2713
  97. Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica. 2007;92:1149–1150
  98. Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007;138:330–337
  99. Reece DE, Rodriguez GP, Chen C, Trudel S, Kukreti V, Mikhael J, et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol. 2008;26:4777–4783
  100. Fenk R, Michael M, Zohren F, Graef T, Czibere A, Bruns I, et al. Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk Lymphoma. 2007;48:2345–2351
  101. Hrusovsky I, Heidtmann H-H. Combination therapy of bortezomib with bendamustin in elderly patients with advanced multiple myeloma (Clinical observation [abstract]). ASH Annual Meeting Abstracts. 2007;110:4851
  102. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525–4530
  103. Zangari M, Barlogie B, Burns MJ, Bolejack V, Hollmig KA, van Rhee F, et al. Velcade (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-term follow-up of phase I-II trial UARK 2001-37: superior outcome in patients with normal cytogenetics and no prior T [abstract]. ASH Annual Meeting Abstracts. 2005;106:2552
  104. Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood. 2007;109:2767–2772
  105. Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia. 2008;22:2247–2256
  106. Richardson PG, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial [abstract]. ASH Annual Meeting Abstracts. 2006;108:405
  107. Richardson P, Jagannath S, Raje N, Jakubowiak A, Lonial S, Ghobrial I, et al. Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): preliminary results of a phase II study. ASH Annual Meeting Abstracts. 2007;110:2714
  108. Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant. 2008;42:413–420
  109. Stadtmauer E, Weber D, Dimopolous M, Belch A, Attal M, Prince M, et al. Lenalidomide in combination with dexamethasone is more effective than dexamethasone at first relapse in relapsed multiple myeloma [abstract]. ASH Annual Meeting Abstracts. 2006;108:3552
  110. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008;112:4445–4451
  111. Knop S, Gerecke C, Topp MS, Liebisch P, Hess G, Kotkiewitz S, et al. Lenalidomide (Revlimid), Adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma—first results of a German multicenter phase I/II trial. ASH Annual Meeting Abstracts. 2006;108:408
  112. Morgan GJ, Schey S, Wu P, Srikanth M, Phekoo KJ, Jenner MW, et al. Lenolidamide (Revlimid), in combination with cyclophosphamide and dexamethasone (CRD) is an effective regimen for heavily pre-treated myeloma patients [abstract]. ASH Annual Meeting Abstracts. 2006;108:3555

PII: S0037-1963(09)00005-5

doi: 10.1053/j.seminhematol.2009.01.004

Seminars in Hematology
Volume 46, Issue 2 , Pages 143-157 , April 2009

Article Tools